RXDX Stock - Prometheus Biosciences, Inc.
Unlock GoAI Insights for RXDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $6.81M | $3.13M | $1.23M | $1.12M | N/A |
| Gross Profit | $6.81M | $3.13M | $1.23M | $1.12M | N/A |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-145,778,000 | $-87,803,000 | $-29,007,000 | $-15,968,000 | $-100,684,000 |
| Net Income | $-141,752,000 | $-89,937,000 | $-39,253,000 | $-30,493,000 | $-103,639,000 |
| Net Margin | -2081.8% | -2874.3% | -3193.9% | -2727.5% | N/A |
| EPS | $-3.49 | $-2.87 | $-1.13 | $-1.13 | $-2.69 |
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 10th 2023 | Jefferies | Downgrade | Hold | $200← $160 |
| July 20th 2022 | Goldman | Initiation | Buy | $51 |
| June 10th 2022 | Piper Sandler | Initiation | Overweight | $53 |
Earnings History & Surprises
RXDXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2023 | Aug 10, 2023 | $-0.91 | $-0.86 | +5.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.91 | $-0.86 | +5.5% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.92 | $-0.86 | +6.5% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.92 | $-0.86 | +6.5% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.91 | $-0.90 | +1.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.89 | $-0.90 | -1.1% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.92 | $-0.86 | +6.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.78 | $-0.82 | -5.1% | ✗ MISS |
Q1 2022 | Mar 9, 2022 | $-0.65 | $-0.77 | -18.5% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.62 | $-0.70 | -12.9% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.38 | $-0.49 | -28.9% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.37 | $-1.67 | -351.4% | ✗ MISS |
Q1 2021 | Mar 12, 2021 | — | $-0.32 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.26 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.31 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.49 | — | — |
Q4 2017 | Nov 7, 2017 | — | $-0.51 | — | — |
Q4 2017 | Nov 7, 2017 | — | $-0.51 | — | — |
Q3 2017 | Aug 8, 2017 | — | $-0.56 | — | — |
Q3 2017 | Aug 8, 2017 | — | $-0.56 | — | — |
Latest News
Frequently Asked Questions about RXDX
What is RXDX's current stock price?
What is the analyst price target for RXDX?
What sector is Prometheus Biosciences, Inc. in?
What is RXDX's market cap?
Does RXDX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RXDX for comparison